Jyong Biotech Ltd (MENS)
Jyong Biotech Ltd. is a biotechnology company focused on developing and commercializing plant-derived therapies for urinary system diseases. Its pipeline includes MCS-2 for benign prostatic hyperplasia and lower urinary tract symptoms, PCP for prostate cancer, and a program for interstitial cystitis and bladder pain syndrome. The company targets markets in the United States, the European Union, and Asia. Founded in 2002, Jyong Biotech is headquartered in New Taipei City, Taiwan. Its common stock trades on the NASDAQ under the symbol MENS.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MENS
|
$2.09
|
-10.1% Downside
|
Fair
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
—
|
-36.9x
|
-6.9x
|
—
|
172.2 M
|
189.6 M
|
9.7%
|
36.3%
|
-10.2
|
—
|
65.1%
|
